Memphasys Ltd (ASX:MEM, OTC:MPHSF, FRA:IG7) has secured its first commercial partnership in South-East Asia, signing an exclusive agreement with TMSC Viet Nam Medical Technology Company Limited for the sale and distribution of its Felix™ sperm separation system in Vietnam.
The two-year agreement is valued at A$530,000 and marks a further expansion of Memphasys’ international commercialisation network, which already covers Europe, MENA, Japan and India.
“Vietnam is exactly the kind of market Felix™ was built for; a sophisticated, high-growth IVF sector that is actively looking for clinical tools that improve outcomes and reduce procedural complexity. TMSC Vietnam brings deep local knowledge in reproductive health and a genuine commitment to advancing fertility care in Vietnam. This agreement does not only open a new geography, it confirms our commercial model is globally scalable to new markets. We are looking forward to working alongside the TMSC Vietnam team to introduce Felix™ to Vietnamese clinicians and we are confident in the opportunity ahead,” chair of the Memphasys Commercialisation Committee Marjan Mikel said.
Agreement structure
The contract comprises A$205,000 in expected value in Year 1 and A$325,000 in Year 2, with quarterly cartridge order growth built into the arrangement.
TMSC Vietnam has placed an initial order for 100 Felix™ cartridges and 3 consoles to support in-market testing and clinical preparation ahead of commercial launch.
Full sales are expected to begin once Vietnamese regulatory approval is received. Felix™ has been confirmed as a Class B medical device in Vietnam, with registration expected in August 2026.
"Vietnam's fertility sector is growing rapidly, and clinicians here are actively seeking technologies that deliver better outcomes for patients. Felix™ addresses a genuine clinical need, it is a sophisticated, evidence-based platform that we believe will resonate strongly with IVF specialists across the country. We are proud to be bringing this technology to Vietnam and look forward to working closely with the Memphasys team to establish Felix™ as the standard of care for sperm preparation in Vietnamese fertility clinics," Director of TMSC Viet Nam Medical Technology Company Limited Mrs. Truong Cam Van, said.
What it means for Memphasys
The agreement gives Memphasys a foothold in Vietnam’s growing assisted reproductive technology market and supports the company’s strategy of building contracted sales through distribution-led and direct engagement channels.
The arrangement mirrors its commercial model in the MENA region, where it works alongside its partner on product education, clinical positioning and market development.
About TMSC Vietnam
TMSC Vietnam is a Hanoi-based medical technology company focused on reproductive health, diagnostics, digital health tools and medical device distribution.
The company has experience in male fertility products and has developed OvumB, an AI-powered ovulation tracking and fertility support application.
Its existing fertility sector focus and healthcare relationships are expected to support the introduction of Felix™ to IVF and ART clinics across Vietnam.
What’s next
The company will now look to complete the Vietnamese regulatory submission process, in-market testing using the initial cartridge and console order, and the first commercial order in the September quarter of 2026, expected to total about A$50,000.
Memphasys also plans to continue developing its broader South-East Asian distribution strategy as it seeks to expand Felix™ into high-value fertility markets.